New developments in diagnosing and treating diabetic foot infections

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue SUPPL. 1, 2008, Pages

  Lipsky, Benjamin A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Antimicrobial therapy; Diabetic foot infection; Diagnosis of infection; Microbiology

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIOPHAGE DNA; BEE VENOM; CEFTOBIPROLE; COLISTIN; DALBAVANCIN; DAPTOMYCIN; DERMACYN; ERTAPENEM; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IODIDE; LINEZOLID; MOXIFLOXACIN; OXYGEN; PENICILLIN G; PEXIGANAN ACETATE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE INTAKE; ERADICATION THERAPY; FOOT ULCER; GLYCEMIC CONTROL; HUMAN; HYPERBARIC OXYGEN; INFECTION; INFECTION RISK; LIMB AMPUTATION; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL VASCULAR DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; TREATMENT FAILURE; VACUUM ASSISTED CLOSURE; WOUND DRESSING;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; DIABETIC FOOT; DRUG RESISTANCE, MICROBIAL; HUMANS; INCIDENCE; INFECTION; WOUNDS AND INJURIES;

EID: 44949162188     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.828     Document Type: Conference Paper

References (65)

1. Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004; 20(Suppl. 1): S68-S77.
2. Lipsky BA, Berendt AR, Deery HG II, et al. IDSA guidelines: diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39: 885-910.
3. Bernard L, for the Société de Pathologie Infectieuse de Langue Française. Management of diabetic foot infections. Méd Mal Infect 2007; 37: 14-25.
4. Pinzur MS, Slovenkai MP, Trepman E, Shields NN. Guidelines for diabetic foot care: recommendations endorsed by the diabetes committee of the American orthopaedic foot and ankle society. Foot Ankle Int 2005; 26: 113-119.
5. Frykberg RG. A summary of guidelines for managing the diabetic foot. Adv Skin Wound Care 2005; 18: 209-214.
6. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the infectious diseases society of America's diabetic foot infection classification system. Clin Infect Dis 2007; 44: 562-565.
7. Lipsky BA, Sheehan P, Armstrong DG, Tice AD, Polis AB, Abramson MA. Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial. Int Wound J 2007; 4: 30-38.
8. Lipsky BA, Armstrong DG, Morgenstern DE, Abramson MA. Does a diabetic foot infection (DFI) wound score correlate with the clinical response to antibiotic treatment? Data from the SIDESTEP study. Diabetologia 2006; 48(Suppl. 1): A354.
9. Lipsky BA, Holroyd KH. Clinical response to pexiganan cream 1% compared to oral ofloxacin for the treatment of infected diabetic foot ulcers. ADA Annual Scientific Meeting, San Diego, CA, June 19, 1999; Abstract 517.
10. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38: 17-24.
11. Lamb HM, Wiseman I.R. Pexiganan acetate. Drugs 1998; 56: 1047-1052, discussion 1053-1044.
12. Ge Y, MacDonald D, Henry MM, et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 1999; 35: 45-53.
13. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005; 366: 1695-1703.
14. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infection in individuals with diabetes. Diabetes Care 2006; 29: 1288-1293.
15. Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007; 50: 18-25.
16. Pellizzer G, Strazzabosco M, Presi S, et al. Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med 2001; 18: 822-827.
17. Kessler L, Piemont Y, Ortega F, et al. Comparison of microbiological results of needle puncture vs. superficial swab in infected diabetic foot ulcer with osteomyelitis. Diabet Med 2006; 23: 99-102.
18. Zuluaga AF, Galvis W, Jaimes P, Vesga O. Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational study. BMC Infect Dis 2002; 2: 8.
19. Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis 2006; 42: 57-62.
20. Slater RA, Lazarovitch T, Boldur I, et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med 2004; 21: 705-709.
21. Citron DM, Goldstein EJC, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate to severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007; 45: 2051-2056.
22. Viswanathan V, Jasmine JJ, Snehalatha. C, Ramachandran A. Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. J Assoc Physicians India 2002; 50: 1013-1016.
23. Game F, Jeffcoate W. MRSA and osteomyehtis of the foot in diabetes. Diabet Med 2004; 21 (Suppl. 4): 16-19.
24. Stanaway S, Johnson D, Moulik P, Gill G. Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res Clin Pract 2007; 75: 47-50.
25. Carvalho CB, Neto RM, Aragao LP, Oliveira MM, Nogueira MB, Ford AC. Diabetic foot infection: bacteriologic analysis of 141 patients. Arq Bras Endocrinol Metabol 2004; 48: 406-413.
26. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003; 20: 159-161.
27. Wagner A, Reike H, Angelkort B. Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant staphylococcus aureus infections. Dtsch Med Wochenschr 2001; 126: 1353-1356.
28. Tentolouris N, Petrikkos G, Vallianou N, et al. Prevalence of methicillin-resistant staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect 2006; 12: 186-189.
29. Shankar EM, Mohan V, Premalatha. G, Srinivasan RS, Usha AR. Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med 2005; 16: 567-570.
30. Yoga R, Khairul A, Sunita K, Suresh C. Bacteriology of diabetic foot lesions. Med J Malaysia 2006; 61(Suppl. A): 14-16.
31. Kandemir O, Akbay E, Sahin E, Milcan A, Gen R. Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. J Infect 2007; 54: 439-445.
32. Lipsky BA, Hait HI, Holroyd KJ. Results and prognostic value of Gram stain of tissue curettage specimens of infected diabetic foot ulcers. Abstract 147, Infectious Disease Society of America 37th Annual Meeting, Philadelphia, PA, 1999.
33. Casman EA. The potential of next-generation microbiological diagnostics to improve bioterrorism detection speed. Risk Anal 2004; 24: 521-536.
34. Heller MJ. DNA microarray technology: devices, systems, and applications. Annu Rev Biomed Eng 2002; 4: 129-153.
35. Sotto A, Richard J-L, Jourdan N, Combescure C, Bouziges N, Lavigne J-P. Miniaturized oligonucleotide arrays: a new tool for discriminating colonization from infection due to Staphylococcus; aureus in diabetic foot ulcers. Diabetes Care 2007; 30: 2819-2828.
36. Lipsky BA. Diabetic foot infections: microbiology made modern? Array of hope. Diabetes Care 2007; 30: 2171-2172.
37. Tan PL, Teh J. MRI of the diabetic foot: differentiation of infection from neuropathic change. Br J Radiol 2006; 80: 939-948.
38. Gil HC, Morrison WB. MR imaging of diabetic foot infection. Semin Musculoskelet Radiol 2004; 8: 189-198.
39. Kumar V. Radiolabeled white blood cells and direct targeting of micro-organisms for infection imaging. Q J Nucl Med Mol Imaging 2005; 49: 325-338.
40. Dumarey N, Egrise D, Blocklet D, et al. Imaging infection with 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med 2006; 47: 625-632.
41. Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med 2006; 23: 348-359.
42. Bergin SM, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database Syst Rev 2006; 25(1): CD005082.
43. Flynn J. Povidone-iodine as a topical antiseptic for treating and preventing wound infection: a literature review. Br J Community Nurs 2003; 8: S36-S42.
44. Nelson EA, O'Meara S, Craig D, et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol Assess 2006; 10: 1-238.
45. Goretti C, Mazzurco, S, Nobili LA, et al. Clinical outcomes of wide postsurgical lesions in the infected diabetic foot managed with 2 different local treatment regimes compared using a quasi-experimental study design: a preliminary communication. Int J Low Extrem Wounds 2007; 6: 22-27.
46. Zahumensky E. Infections and diabetic foot syndrome in field practice. Vnitr Lek 2006; 52: 411-416.
47. Heijink A, Yaszemski MJ, Patel R, Rouse MS, Lewallen DG, Hanssen AD. Local antibiotic delivery with OsteoSet, DBX, and Collagraft. Clin Orthop Relat Res 2006; 451: 29-33.
48. Armstrong DG, Findlow AH, Oyibo SO, Boulton AJ. The use of absorbable antibiotic-impregnated calcium sulphate pellets in the management of diabetic foot infections. Diabet Med 2001; 18: 942-943.
49. Armstrong DG, Stephan KT, Espensen EH, Lipsky BA, Boulton AJM. What is the shelf-life of physician-mixed antibiotic-impregnated calcium sulfate pellets? J Foot Ankle Surg 2003; 42: 302-304.
50. Andros G, Armstrong DG, Attinger CE, et al. Consensus statement on negative pressure wound therapy (V.A.C. Therapy) for the management of diabetic foot wounds. Ostomy Wound Manage 2006; 52(Suppl): 1-32.
51. Dang CN, Anwar R, Thomas G, Prasad YD, Boulton AJ, Malik RA. The Biogun: A novel way of eradicating methicillin-resistant Staphylococcus aureus colonization in diabetic foot ulcers. Diabetes Care 2006; 29: 1176.
52. Lipsky BA. The Biogun: a novel way of eradicating methicillin-resistant Staphylococcus aureus colonization in diabetic foot ulcers. Response to Dang, et al. Diabetes Care 2006; 29: 2181, author reply 2181-2182.
53. Shasha SM, Sharon N, Inbar M. Bacteriophages as antibacterial agents. Harefuah 2004; 143: 121-125, 166.
54. Weber-Dabrowska B, Mulczyk M, Gorski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch Immunol Ther Exp (Warsz) 2000; 48: 547-551.
55. Bowling FL, Salgami EV, Boulton AJ. Larval therapy: a novel treatment in eliminating methicillin-resistant Staphylococcus aureus from diabetic foot ulcers. Diabetes Care 2007; 30: 370-371.
56. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005; 55: 240-245.
57. Lipsky BA, Giordano P, Chodri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared to piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother 2007; 60: 370-376.
58. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006; 50: 3959-3962.
59. Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez HT. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 2006; 50: 2875-2879.
60. Tascini C, Gemignani G, Palumbo F, et al. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 2006; 18: 648-651.
61. Tascini C, Menichetti F, Gemignani G, et al. Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis. Int J Low Extrem Wounds 2006; 5: 213-216.
62. Sedivy J, Petkov V, Jirkovska A, et al. Optimization of amoxicillin/clavulanate therapy based on pharmacokinetic/pharmacodynamic parameters in diabetic foot infection patients. Klin Mikrobiol Infekc Lek 2004; 10: 167-175.
63. Kranke P, Bennett M, Roeckl-Wiedmann I, Debus S. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2004; (2): CD004123.
64. Berendt AR. Counterpoint: hyperbaric oxygen for diabetic foot wounds is not effective. Clin Infect Dis 2006; 43: 193-198.
65. Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis. Diabetes Care 2005; 28: 454-460.